Characterizing the Treatment Courses of Ranibizumab and Panretinal Photocoagulation for Retinopathy of Prematurity

医学 血管抑制剂 早产儿视网膜病变 全视网膜光凝术 眼科 视网膜病变 眼病 激光凝固 视网膜 验光服务
作者
Victoria Vought,Rita Vought,Alexander B Crane,Suqin Guo,Neelakshi Bhagat,Marco A. Zarbin,Rudolph S. Wagner
出处
期刊:Journal of Pediatric Ophthalmology & Strabismus [Slack Incorporated (United States)]
卷期号:: 1-9
标识
DOI:10.3928/01913913-20251204-07
摘要

PURPOSE: This study characterizes the treatment course and outcomes of infants with retinopathy of prematurity (ROP) treated with ranibizumab, panretinal photo-coagulation (PRP), or combined therapy. METHODS: This retrospective chart review analyzed electronic health record data of infants treated for ROP between 2016 and 2024 at a single academic center. RESULTS: Thirty-seven infants (72 eyes) were analyzed (59.05% male, average 24.7 ± 1.4 weeks). At first treatment, most eyes were zone II, stage 3+ (59.7%). All eyes had plus disease except six treated for persistent avascular retina. PRP was administered as initial therapy for 30 (41.7%) eyes and ranibizumab for 42 (58.3%). Thirty-five eyes (48.6%) underwent only one treatment of either PRP (26 eyes; 36.1%) or ranibizumab (9 eyes; 12.5%). A second treatment consisting of ranibizumab was administered in 4 (13.3%) of 30 eyes treated with PRP and 21 (50%) of 42 eyes injected with ranibizumab. Eight eyes (11.1%) had three treatments: two ranibizumab injections followed by PRP. Four eyes (5.6%) had four treatments: three ranibizumab injections followed by PRP. ROP reactivation occurred in 14 (19.4%) eyes that all received ranibizumab injection initially (mean 50.6 ± 16.7 days after most recent injection). Final outcomes included PRP for persistent avascular retina in 22 (30.6%) eyes, unknown final outcomes due to lost follow-up for 16 (22.2%), documented resolution in 33 (45.8%), and scleral buckling for a peripheral retinal detachment (stage 4a) for one (1.4%). CONCLUSIONS: Ranibizumab was initiated at a younger age with higher retreatment and reactivation events compared to PRP, underscoring variability in real-world ROP treatment patterns and outcomes.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
wang完成签到 ,获得积分10
3秒前
xipding完成签到,获得积分10
3秒前
5秒前
huluwa完成签到,获得积分10
9秒前
yihao完成签到 ,获得积分10
10秒前
刘较瘦完成签到,获得积分10
12秒前
科研人完成签到,获得积分10
12秒前
雪山大地发布了新的文献求助10
12秒前
花火妖妖完成签到,获得积分10
17秒前
长孙烙完成签到 ,获得积分10
17秒前
江安弘完成签到,获得积分10
17秒前
hanliulaixi完成签到 ,获得积分10
18秒前
19秒前
文文武完成签到 ,获得积分10
19秒前
活泼红牛完成签到,获得积分10
21秒前
123完成签到,获得积分10
24秒前
菜鸟学习完成签到 ,获得积分10
27秒前
LA完成签到,获得积分10
29秒前
甜美尔烟完成签到,获得积分10
32秒前
Jaycee完成签到 ,获得积分10
32秒前
YMM完成签到,获得积分10
32秒前
SciGPT的应助被活泼雪莲采纳,获得10
36秒前
小叶完成签到 ,获得积分10
39秒前
雪山大地发布了新的文献求助10
39秒前
39秒前
Bi完成签到,获得积分10
40秒前
刘亦菲完成签到 ,获得积分10
41秒前
ldd完成签到,获得积分10
42秒前
lingling完成签到 ,获得积分10
43秒前
快乐香水完成签到 ,获得积分10
45秒前
嗯嗯完成签到 ,获得积分0
46秒前
书意完成签到 ,获得积分10
47秒前
timeless完成签到 ,获得积分10
49秒前
李东东完成签到 ,获得积分10
51秒前
汉堡包的应助被Son4904采纳,获得10
52秒前
52秒前
wp981308530完成签到,获得积分10
52秒前
活泼雪莲完成签到,获得积分10
52秒前
56秒前
香蕉觅云的应助被Jasmine采纳,获得10
56秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
John McDowells Bildungstheorie 800
八旗制度の研究 600
Hidden Empire of Finance: How Wall Street Profits from Our Cities and Fuels Global Inequality 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8166550
求助须知:如何正确求助?哪些是违规求助? 9559535
关于积分的说明 21750720
捐赠科研通 7757357
什么是DOI,文献DOI怎么找? 3429141
关于科研通互助平台的介绍 2553523
邀请新用户注册赠送积分活动 2473904